公开(公告)号：US10752691B2

公开(公告)日：2020-08-25

申请号：US16352709

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00 ,  C12N15/85 ,  A61P35/02 ,  C07K14/55

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20200010554A1

公开(公告)日：2020-01-09

申请号：US16494962

申请日：2018-03-03

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Josephine Salimu ,  Kevin Moulder ,  Beatriz Goyenechea Corzo ,  Pascal Merchiers ,  Sergio Quezada ,  Karl Peggs ,  Frederick Arce Vargas ,  Isabelle Solomon

IPC: C07K16/28 ,  C07K14/55

Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

公开(公告)号：US20190284287A1

公开(公告)日：2019-09-19

申请号：US16352717

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.